The purpose of this study is to evaluate the retention in tumour and distribution behavior of \[Lu-177\]-Catalase after intratumoral injection,and preliminary evaluation the efficacy and safety of \[Lu-177\]-Catalase.
Male or female patients, aged 18-70 years; ECOG score 0 or 1;
Patients with advanced malignant tumors, such as liver cancer, ovarian cancer, prostate cancer, and so on, clearly diagnosed by pathology and/or cytology;
Patients with advanced solid tumors who have failed or cannot tolerate standard treatment;
Expected survival of more than 3 months;
Severe abnormal liver and kidney function;
Pregnant, pregnant and lactating women;
Can not lie flat for half an hour;
Refuse to join the clinical investigator;
Single group
[ Lu-177]-Catalase
Drug\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
The absorbed radiation dose of tumor and normal organs
Calculation of effective absorbed dose of tumor in situ injection
Preliminary efficacy of [ Lu-177]-Catalase based on tumor response
Tumor volume based on RECIST 1.1.
Adverse events for [ Lu-177]-Catalase
Occurrence of adverse events for \[ Lu-177\]-Catalase
Click on the lead sponsor to view all of their trials.
